New! ACIP recommends routine vaccination of males 11 through 21 years old against human papillomavirus infection

On December 23, 2011, CDC issued updated recommendations of the Advisory Committee on Immunization Practices for vaccinating males with quadrivalent human papillomavirus vaccine (HPV4; Gardasil; Merck). HPV4 is directed against human papillomavirus (HPV) types 6, 11, 16, and 18. One of ACIP’s primary goals in recommending that males be vaccinated is to protect them against some anal, penile, and oropharyngeal cancers caused primarily by HPV type 16. Previously, ACIP had recommended permissive use of HPV4 in males age 9–26 years for the prevention of genital warts.

Following are the recommendations published in MMWR (www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm) for administering HPV4 to males:

- Routinely vaccinate males age 11–12 years with a 3-dose series of HPV4. The series can be started in males as young as age 9.
- Vaccinate males age 13 through 21 if they have not been vaccinated previously or have not completed the 3-dose series.
- Males age 22 through 26 years may be vaccinated.

This means that any male in this age range who wishes to be protected against human papillomavirus may receive the 3-dose series of HPV4 vaccine.

- Routinely vaccinate males through age 26 years if they are immunocompromised as a result of infection (including HIV), disease, or medications and have not been vaccinated previously or have not completed the 3-dose series.
- Routinely vaccinate men who have sex with men (MSM) through age 26 if they have not been vaccinated previously or have not completed the 3-dose series. MSM are at higher risk for infection with HPV types 6, 11, 16, and 18 and associated conditions, including genital warts and anal cancer.

And be sure to continue vaccinating young women with HPV vaccine. HPV vaccine is routinely recommended for young women age 11 through 26 years. According to CDC National Immunization Survey data, only 49% of females 13–17 years have started their HPV series and only 32% have completed the 3-dose series. There is lots of work to do!

(continued on page 10)
Immunization Action Coalition and CDC are official partners in providing VIS translations

If you are a healthcare professional who provides vaccination services to people who don’t speak English, the Immunization Action Coalition (IAC) is the “go-to” spot for translations of Vaccine Information Statements (VISs). For more than a decade, IAC has made these translations available on immunize.org. The VIS translations in up to 40 languages are donated to IAC from generous partners and volunteers. In October 2011, IAC entered into a cooperative agreement with the Centers for Disease Control and Prevention (CDC) to support IAC’s role as the official clearinghouse of VIS translations. In addition, as a result of this federal funding and effective immediately, IAC will consistently provide translations in seven languages for each routinely recommended VIS whenever VISs are newly updated by CDC. The languages we will provide (within 30 days of CDC’s release of an English VIS) are:

- Arabic
- Chinese (Traditional)
- French (European)
- Russian
- Spanish (Mexican)
- Somali
- Vietnamese

IAC’S GENEROUS TRANSLATION PARTNERS

IAC would like to take this opportunity to acknowledge the contributions of our generous translation partners, who we will continue to count on to provide VISs in additional languages. We are grateful for their time and dedication to providing these helpful patient materials.

- Arkansas Department of Health
- Asian Pacific Health Care Venture
- California Department of Public Health, Immunization Branch
- DT Interpreting and Wentworth Douglass Hospital
- Hawaii Department of Health
- Healthy Roads Media
- Kentucky Department of Public Health
- Massachusetts Department of Public Health
- Minnesota Department of Health
- Mustafa Kozanoglu, MD, Dogus Child Healthcare Center, Adana, Turkey
- New York City Department of Health and Mental Hygiene
- Oregon Public Health Division, Immunization Program
- Yisehak Tura, RN

DISCLAIMER: Vaccinate Adults! is available to all readers free of charge. Some of the information in this issue is supplied to us by the Centers for Disease Control and Prevention in Atlanta, Georgia, and some information is supplied by third-party sources. The Immunization Action Coalition (IAC) has used its best efforts to accurately publish all of this information, but IAC cannot guarantee that the original information as supplied by others is correct or complete, or that it has been accurately published. Some of the information in this issue is created or compiled by IAC. All of the information in this issue is of a time-critical nature, and we cannot guarantee that some of the information is not now outdated, inaccurate, or incomplete. IAC cannot guarantee that reliance on the information in this issue will cause no injury. Before you rely on the information in this issue, you should first independently verify its current accuracy and completeness. IAC is not licensed to practice medicine or pharmacology, and the providing of the information in this issue does not constitute such practice. Any claim against IAC must be submitted to binding arbitration under the auspices of the American Arbitration Association in St. Paul, Minnesota.
Wallet-sized immunization record cards for all ages: For adults, children & teens, and for a lifetime!

Now you can give any patient a permanent vaccination record card designed specifically for their age group: child & teen, adult, or lifetime. These brightly colored cards are printed on durable rip-, smudge-, and water-proof paper. To view the cards or for more details, go to www.immunize.org/shop and click on the images.

Buy 1 box (250 cards) for $45 (first order of a 250-card box comes with a 30-day, money-back guarantee). Discounts for larger orders: 2 boxes $40 each; 3 boxes $37.50 each; 4 boxes $34.50 each

To order, visit www.immunize.org/shop, or use the order form on page 12.

For healthcare settings in California, contact your local health department immunization program for a free copy.

"Immunization Techniques — Best Practices with Infants, Children, and Adults"

The California Department of Public Health, Immunization Branch, updated its award-winning training video, "Immunization Techniques: Best Practices with Infants, Children, and Adults." The 25-minute DVD can be used to train new employees and to refresh the skills of experienced staff on administering injectable, oral, and nasal-spray vaccines to children, teens, and adults. Make sure your healthcare setting has the 2010 edition!

The cost is $17 each for 1–9 copies; $10.25 each for 10–24 copies; $7 each for 25–49 copies; $5.75 each for 50–99 copies.

To order, visit www.immunize.org/shop, or use the order form on page 12.

For 100 or more copies, contact us for discount pricing: admininfo@immunize.org

IAC Honors Healthcare Institutions With Stellar Influenza Vaccination Policies

IAC’s Honor Roll for Patient Safety recognizes hospitals, professional societies, and government entities that have taken a stand for patient safety by creating strong mandatory influenza vaccination policies for healthcare workers. More than 150 organizations are now enrolled.

Read the position statements of leading medical organizations and see the organizations now enrolled. You can apply for your organization to become a member. Access the Honor Roll at www.immunize.org/honor-roll

Advisory Board

Liaisons from Organizations
Bernadette A. Albanese, MD, MPH
Council of State & Territorial Epidemiologists
William L. Atkinson, MD, MPH
Nat’l Ctr. for Immun. & Resp. Diseases, CDC
Stephen L. Cochi, MD, MPH
Nat’l Ctr. for Immun. & Resp. Diseases, CDC
Lawrence J. D’Angelo, MD, MPH
Society for Adolescent Health and Medicine
Paul Etzkind, DrPH, MPH
Nat’l. Asso. of County & City Health Officials
Stanley A. Gali, MD
Amer. College of Obstetricians & Gynecologists
Bruce Gellin, MD, MPH
National Vaccine Program Office, DHHS
Neal A. Halsey, MD
Institute for Vaccine Safety, Johns Hopkins Univ.
Claire Hannan, MPH
Association of Immunization Managers
Carol E. Hayes, CNM, MN, MPH
American College of Nurse-Midwives
Gregory James, DO, MPH, FACOFP
American Osteopathic Association
Samuel L. Katz, MD
Pediatric Infectious Diseases Society
Marie-Michele Leger, MPH, PA-C
American Academy of Physician Assistants
Harold S. Margolis, MD
Nat’l Ctr. for Emerg. & Zoonotic Inf. Diseases, CDC
Martin G. Myers, MD
National Network for Immunization Information
Kathleen M. Neuzil, MD, MPH
American Academy of Physicians
Paul A. Offit, MD
Vaccine Education Ctr., Children’s Hosp. of Phila.
Walter A. Orenstein, MD
Emory Vaccine Center, Emory University
Mitchel C. Rothholz, RPh, MBA
American Pharmacists Association
Thomas N. Saari, MD
American Academy of Pediatrics
William Schaffner, MD
Infectious Diseases Society of America
Anne Schuchat, MD
Nat’l Ctr. for Immun. & Resp. Diseases, CDC
Thomas E. Stenwig, RN, PhD
American Nurses Association
Kathryn L. Tallkington, MPAff
Asm. of State & Territorial Health Officials
Litjen Tan, PhD
American Medical Association
Ann S. Taub, MA, CPNP
National Asso. of Pediatric Nurse Practitioners
John W. Ward, MD
Division of Viral Hepatitis, NCHHSTP, CDC
Patricia N. Whiteley-Williams, MD, MPH
National Medical Association
Walter Williams, MD, MPH
Nat’l Ctr. for Immun. & Resp. Diseases, CDC

Individuals
Hie-Won L. Hann, MD
Jefferson Medical College, Philadelphia, PA
Mark A. Kane, MD, MPH
Consultant, Seattle, WA
Edgar K. Marcuse, MD, MPH
University of Washington School of Medicine
Brian J. McMahon, MD
Alaska Native Medical Center, Anchorage, AK
Stanley A. Plotkin, MD
Vaxconsult.com
Gregory A. Poland, MD
Mayo Clinic, Rochester, MN
Sarah Jane Schwarzenberg, MD
University of Minnesota
Coleman L. Smith, MD
Minnesota Gastroenterology, Minneapolis, MN
Richard K. Zimmerman, MD, MPH
University of Pittsburgh
Vaccine Highlights

Recommendations, schedules, and more

Editor’s note: The information in Vaccine Highlights is current as of February 3, 2012.

The next ACIP meetings

A committee of 15 national experts, the Advisory Committee on Immunization Practices (ACIP) advises CDC on the appropriate use of vaccines. ACIP meets 3 times a year in Atlanta; meetings are open to the public. The next meetings will be held on Feb. 22–23 and June 20–21. For more information, visit www.cdc.gov/vaccines/recs/acip.

ACIP periodically issues public health recommendations on the use of vaccines. Clinicians who vaccinate should have a current set for reference. Published in the Morbidity and Mortality Weekly Report (MMWR), ACIP recommendations are easily available. Here are sources:

- Download them from links on IAC’s website: www.immunize.org/acip.

- Download them from CDC’s website: www.cdc.gov/vaccines/pubs/acip-list.htm.

New ACIP recommendations

On Feb. 3, 2012, CDC published “Recommended Adult Immunization Schedule—United States, 2012” as a QuickGuide. To obtain a copy of the schedule, see the seven pages at the end of the MMWR issue located at www.cdc.gov/mmwr/pdf/wk/mm6104.pdf.

On Dec. 23, 2011, MMWR published “Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males.” ACIP recommends routine vaccination of males age 11 or 12 years with quadrivalent human papillomavirus vaccine (HPV4; Gardasil; Merck) administered as a 3-dose series that can be started in males as young as age 9 years. Vaccination is also recommended for males age 13 through 21 years who have not been vaccinated previously or have not completed the series. Males age 22 through 26 years may be vaccinated.

ACIP also recommends vaccination with HPV4 in males 22–26 who are immunocompromised and for men who have sex with men. To obtain a copy of the recommendations, see pages 1705–1708 of the MMWR issue located at www.cdc.gov/mmwr/pdf/wk/mm6104.pdf.

On Dec. 23, 2011, CDC published ACIP recommendations titled “Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus.” ACIP recommends that hepatitis B vaccine be administered to unvaccinated adult diabetics age 19 through 59 years. The recommendations also state that hepatitis B vaccine may be administered to unvaccinated diabetics age 60 years and older at the discretion of the treating clinician. To obtain a copy of the recommendations, see pages 1709–1711 of the MMWR issue located at www.cdc.gov/mmwr/pdf/wk/mm6050.pdf.

On Nov. 25, 2011, CDC published ACIP recommendations titled Immunization of Health-Care Personnel. To obtain a copy, go to www.cdc.gov/mmwr/pdf/tr/rr6007.pdf.

Other vaccine news

On Nov. 11, 2011, CDC published “Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years.” It states that at its June 2011 meeting, ACIP declined to recommend use of herpes zoster (shingles) vaccine for adults age 50 through 59 years and reaffirmed its current recommendation that the vaccine be routinely recommended for adults age 60 years and older. ACIP cited the limited supply of Zostavax as a concern in recommending an expanded age indication for the vaccine. ACIP will continue to monitor supply issues and might update recommendations regarding vaccination of adults age 50 through 59 years when an adequate and stable supply of the vaccine is assured. To access the article, see page 1528 of the MMWR issue located at www.cdc.gov/mmwr/pdf/wk/mm6044.pdf.

On Dec. 30, 2011, FDA issued a press release announcing that it has approved the use of the pneumococcal 13-valent conjugate vaccine, Prevnar 13 (Pfizer), to prevent pneumonia and invasive disease caused by the bacterium Streptococcus pneumoniae in people age 50 and older. Prevnar 13 was originally approved on Feb. 24, 2010, for use in infants and children age 6 weeks through 5 years. The FDA press release is available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm.

New VIs


On Jan. 24, 2012, CDC issued an updated VIS for Td and Tdap vaccines. It incorporates updated ACIP recommendations regarding children age 7 through 9 years, adults 65 and older, and pregnant women. It also includes a paragraph about the risk of syncope. Because of the addition of risk information, CDC encourages providers to begin using the updated edition as soon as possible. To access the VIS, go to www.immunize.org/vis/td_tdap.pdf.

On Dec. 7, 2011, CDC released a revised Japanese encephalitis (JE) vaccine VIS. To access it, go to www.immunize.org/vis/je_rixiaro.pdf.

Subscribe to IAC Express!

www.immunize.org/subscribe

Get weekly updates on vaccine information while it’s still news!

All the news we publish in “Vaccine Highlights” will be sent by email to you every Tuesday. Free! To sign up, visit www.immunize.org/subscribe

At the same time, you’ll be able to sign up to receive other free IAC publications!

New and updated VISs

The use of most Vaccine Information Statements (VISs) is mandated by federal law. Listed below are the dates of the most current VISs. Check your stock of VISs against this list. If you have outdated VISs, print current ones from IAC’s website at www.immunize.org. You’ll find VISs in more than 30 languages.

- DTap/DT/DTaP ..... 5/17/07
- Hepatitis A ..... 10/25/11
- Hepatitis B ..... 2/2/12
- Hib ..... 12/16/98
- HPV (Cervarix) ..... 5/3/11
- HPV (Gardasil) ..... 5/3/11
- Influenza (LAIV) ..... 7/26/11
- Influenza (IV) ..... 7/26/11
- Japan. enceph. ..... 12/6/10
- Meningococcal 10/14/11
- MMR ..... 3/3/10

Multi-vaccine VIS ..... 9/18/08
(fod 6 vaccines given to infants/children: DTap, IPV, Hib, HepB, PCV, RV)
Use These CDC Fact Sheets to Keep Patients and Staff Up to Date on Vaccine Topics

Ensuring the Safety of Vaccines in the United States

- Especially, the United States has the same, strict effective vaccine safety in its history.
- The United States has a long-standing history of safety policies that ensure vaccines are safe for use in the general population. These policies are in place to ensure that vaccines are safe for use in children, adults, and elderly individuals.
- The U.S. Food and Drug Administration (FDA) ensures the safety, effectiveness, and quality of vaccines to the United States. Before the U.S. FDA approves a vaccine for use, it must undergo extensive testing and evaluation.
- The FDA also has a program called VAERS that monitors adverse events that occur after vaccination. VAERS receives and analyzes reports of adverse events that are suspected to be related to vaccination.

Understanding the Vaccine Adverse Event Reporting System (VAERS)

- VAERS collects and analyzes reports of adverse events that are suspected to be related to vaccination. VAERS receives and analyzes reports of adverse events that are suspected to be related to vaccination.
- VAERS is a surveillance system that allows healthcare providers to report adverse events that occur after vaccination. VAERS is designed to identify any safety concerns that have not been identified in clinical trials.

Understanding Thimerosal, Mercury, and Vaccine Safety

- Thimerosal is a preservative that is commonly used in vaccines. Thimerosal is commonly used in vaccines to prevent bacterial contamination.
- Thimerosal is not harmful to the general population. Thimerosal is safe for use in vaccines to prevent bacterial contamination.
- Thimerosal is not used in vaccines for children in the United States.

Understanding How Vaccines Work

- Diseases that vaccines prevent can cause serious illness or death. Vaccines are designed to prevent these illnesses by creating immunity to the disease.
- How Vaccines Work
- Vaccines contain antigens that are similar to the antigens that cause the disease. When the body is exposed to the antigen, it creates antibodies that are able to fight off the disease.
- The body's immune system creates antibodies that are able to fight off the disease. The antibodies are able to fight off the disease by attaching to the antigen.

How to Get These CDC Fact Sheets

- For more information on vaccines, vaccinology, immunology, pediatrics, internal medicine, nursing, family medicine, and vaccine-preventable diseases, visit the Centers for Disease Control and Prevention (CDC) website: http://www.cdc.gov/vaccines/conversations

Download these CDC fact sheets at
www.cdc.gov/vaccines/spec-grps/hcp/provider-resources-safety-sheets.html

Vaccinate Adults! • February 2012 • Immunization Action Coalition • (651) 647-9009 • www.imunize.org • www.vaccineinformation.org
### Summary of Recommendations for Adult Immunization (Age 19 years & older)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccine administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza</strong> Trivalent inactivated influenza vaccine (TIV) Give IM or ID (intradermally) — Live attenuated influenza vaccine (LAIV) Give intranasally</td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.  • Vaccination is recommended for all adults. (This includes healthy adults ages 19–49yrs without risk factors.)  • LAIV is approved only for healthy nonpregnant people age 2–49yrs.  • Adults age 18 through 64yrs may be given any intramuscular TIV product or, alternatively, the intraderal TIV product (Fluzone Intradermal).  • Adults ages 65yrs and older may be given standard-dose TIV or, alternatively, the high-dose TIV (Fluzone High-Dose).  <strong>Note:</strong> LAIV may not be given to some adults; see contraindications and precautions listed in far right column.</td>
<td>• Give 1 dose every year in the fall or winter.  • Begin vaccination services as soon as vaccine is available and continue until the supply is depleted.  • Continue to give vaccine to unvaccinated adults throughout the influenza season (including when influenza activity is present in the community) and at other times when the risk of influenza exists.  • If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.</td>
<td><strong>Contraindications</strong>  • Previous anaphylactic reaction to this vaccine, to any of its components, including egg protein.  • For LAIV only: pregnancy; chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurological/neuromuscular, hematologic, or metabolic (including diabetes) disorders; immunosuppression (including that caused by medications or HIV).  <strong>Precautions</strong>  • Moderate or severe acute illness.  • History of Guillain-Barré syndrome (GBS) within 6wks following previous influenza vaccination.  • For LAIV only: receipt of specific antivirals (i.e., amantadine, rimantadine, oseltamivir) 48hrs before vaccination. Avoid use of these antiviral drugs for 14d after vaccination.</td>
</tr>
</tbody>
</table>

| **Pneumococcal polysaccharide (PPSV) Give IM or SC** | For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at [www.immunize.org/catg.d/p2010.pdf](http://www.immunize.org/catg.d/p2010.pdf).  • People age 65yrs and older.  • People younger than age 65yrs who have chronic illness or other risk factors, including chronic cardiac or pulmonary disease (including asthma), chronic liver disease, alcoholism, diabetes, CSF leaks, cigarette smoking, as well as candidates for or recipients of cochlear implants and people living in special environments or social settings (including American Indian/Alaska Natives age 50 through 64yrs if recommended by local public health authorities).  • Those at highest risk of fatal pneumococcal infection, including people who - Have anatomic or functional asplenia, including sickle cell disease. - Have an immunocompromising condition, including HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, or nephrotic syndrome. - Are receiving immunosuppressive chemotherapy (including corticosteroids). - Have received an organ or bone marrow transplant. | • Give 1 dose if unvaccinated or if previous vaccination history is unknown.  • Give a 1-time revaccination to people  - Age 65yrs and older if 1st dose was given prior to age 65yrs and 5yrs have elapsed since dose #1.  - Age 19 through 64yrs who are at highest risk of fatal pneumococcal infection or rapid antibody loss (see the 3rd bullet in the box to left for listings of people at highest risk) and 5yrs have elapsed since dose #1. | **Contraindication** Previous anaphylactic reaction to this vaccine or to any of its components.  **Precaution** Moderate or severe acute illness. |

---

*This document was adapted from the recommendations of the Advisory Committee on Immunization Practices (ACIP). To obtain copies of these recommendations, call the CDC-INFO Contact Center at (800) 232-4636; visit CDC’s website at [www.cdc.gov/vaccines/pubs/ACIP-list.htm](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm); or visit the Immunization Action Coalition (IAC) website at [www.immunize.org/acip](http://www.immunize.org/acip). This table is revised periodically. Visit IAC’s website at [www.immunize.org/adultrules](http://www.immunize.org/adultrules) to make sure you have the most current version.*
### Summary of Recommendations for Adult Immunization (Age 19 years & older) (Page 2 of 4)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccine administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
| **MMR** (Measles, mumps, rubella)  
- People born in 1957 or later (especially those born outside the U.S.) should receive at least 1 dose of MMR if there is no laboratory evidence of immunity or documentation of a dose given on or after the first birthday.  
- People in high-risk groups, such as healthcare personnel (paid, unpaid, or volunteer), students entering college and other post–high school educational institutions, and international travelers, should receive a total of 2 doses.  
- People born before 1957 are usually considered immune, but evidence of immunity (serology or documented history of 2 doses of MMR) should be considered for healthcare personnel.  
- Women of childbearing age who do not have acceptable evidence of rubella immunity or vaccination.  
- People born in 1957 or later (especially those born outside the U.S.) should receive at least 1 dose of MMR if there is no laboratory evidence of immunity or documentation of a dose given on or after the first birthday.  
- People in high-risk groups, such as healthcare personnel (paid, unpaid, or volunteer), students entering college and other post–high school educational institutions, and international travelers, should receive a total of 2 doses.  
- People born before 1957 are usually considered immune, but evidence of immunity (serology or documented history of 2 doses of MMR) should be considered for healthcare personnel.  
- Women of childbearing age who do not have acceptable evidence of rubella immunity or vaccination.  
- Give 1 dose.  
- If dose #2 is recommended, give it no sooner than 4wks after dose #1.  
- If a pregnant woman is found to be rubella susceptible, give 1 dose of MMR postpartum.  
- If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, Zos, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  
- Within 72hrs of measles exposure, give 1 dose as postexposure prophylaxis to susceptible adults.  
**Note:** Routine post-vaccination serologic testing is not recommended.  
- Give 2 doses.  
- Dose #2 is given 4–8wks after dose #1.  
- If dose #2 is delayed, do not repeat dose #1.  
- If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, Zos, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  
- May use as postexposure prophylaxis if given within 5d.  
**Note:** Routine post-vaccination serologic testing is not recommended.  
- Previous anaphylactic reaction to this vaccine or to any of its components.  
- Pregnancy or possibility of pregnancy within 4wks.  
- Severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy; or severely symptomatic HIV).  
**Note:** HIV infection is NOT a contraindication to MMR for those who are not severely immunocompromised (i.e., CD4+ T-lymocyte counts are greater than or equal to 200 cells/µL).  
**Precautions**  
- Moderate or severe acute illness.  
- If blood, plasma, and/or immune globulin were given in past 11m, see ACIP statement *General Recommendations on Immunization* regarding time to wait before vaccinating.  
- History of thrombocytopenia or thrombocytopenic purpura.  
**Note:** If TST (tuberculosis skin test) and MMR are both needed but not given on same day, delay TST for 4–6wks after MMR. |  
| **Varicella** (chickenpox)  
- All adults without evidence of immunity.  
**Note:** Evidence of immunity is defined as written documentation of 2 doses of varicella vaccine; a history of varicella disease or herpes zoster (shingles) based on healthcare-provider diagnosis; laboratory evidence of immunity; and/or birth in the U.S. before 1980, with the exceptions that follow.  
- Healthcare personnel (HCP) born in the U.S. before 1980 who do not meet any of the criteria above should be tested or given the 2-dose vaccine series. If testing indicates they are not immune, give the 1st dose of varicella vaccine immediately. Give the 2nd dose 4–8 wks later.  
- Pregnant women born in the U.S. before 1980 who do not meet any of the criteria above should either 1) be tested for susceptibility during pregnancy and if found susceptible, given the 1st dose of varicella vaccine postpartum before hospital discharge, or 2) not be tested for susceptibility and given the 1st dose of varicella vaccine postpartum before hospital discharge. Give the 2nd dose 4–8wks later.  
- Give 2 doses.  
- Dose #2 is given 4–8wks after dose #1.  
- If dose #2 is delayed, do not repeat dose #1. Just give dose #2.  
- If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, Zos, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  
- May use as postexposure prophylaxis if given within 5d.  
**Note:** Routine post-vaccination serologic testing is not recommended.  
- Previous anaphylactic reaction to this vaccine or to any of its components.  
- Pregnancy or possibility of pregnancy within 4wks.  
- People on high-dose immunosuppressive therapy or who are immunocompromised because of malignancy and primary or acquired cellular immunodeficiency, including HIV/AIDS (although vaccination may be considered if CD4+ T-lymocyte counts are greater than or equal to 200 cells/µL. See *MMWR 2007;56,RR-4*).  
**Precautions**  
- Moderate or severe acute illness.  
- If blood, plasma, and/or immune globulin (IG or VZIG) were given in past 11m, see ACIP statement *General Recommendations on Immunization* regarding time to wait before vaccinating.  
- Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24hrs before vaccination, if possible; delay resumption of these antiviral drugs for 14d after vaccination. |  
| **Zoster** (shingles)  
*Give SC* | People age 60yrs and older.  
- Give 1-time dose if unvaccinated, regardless of previous history of herpes zoster (shingles) or chickenpox.  
- If 2 or more of the following live virus vaccines are to be given—MMR, Zos, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  
- Previous anaphylactic reaction to any component of zoster vaccine.  
- Primary cellular or acquired immunodeficiency.  
- Pregnancy.  
**Precautions**  
- Moderate or severe acute illness.  
- Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24hrs before vaccination, if possible; delay resumption of these antiviral drugs for 14d after vaccination. |
### Summary of Recommendations for Adult Immunization *(Age 19 years & older)*  

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccine administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
| **Hepatitis A**  
*HepA)*  
**Give IM**  
Brands may be used interchangeably. | For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at www.immunize.org/catg.d/p2010.pdf.  
• All people who want to be protected from hepatitis A virus (HAV) infection and lack a specific risk factor.  
• People who travel or work anywhere EXCEPT the U.S., Western Europe, New Zealand, Australia, Canada, and Japan.  
• People with chronic liver disease; injecting and non-injecting drug users; men who have sex with men; people who receive clotting-factor concentrates; people who work with HAV in experimental lab settings; food handlers when health authorities or private employers determine vaccination to be appropriate.  
• People who anticipate close personal contact with an international adoptee from a country of high or intermediate endemicity during the first 60 days following the adoptee’s arrival in the U.S.  
• Adults age 40yrs or younger with recent (within 2 wks) exposure to HAV. For people older than age 40yrs with recent (within 2 wks) exposure to HAV, immune globulin is preferred over HepA vaccine. | • Give 2 doses, spaced 6–12m apart.  
• If dose #2 is delayed, do not repeat dose #1. Just give dose #2.  
For Twinrix (hepatitis A and B combination vaccine [GSK]) for patients age 18yrs and older only: give 3 doses on a 0, 1, 6m schedule. There must be at least 4wks between doses #1 and #2, and at least 5m between doses #2 and #3. An alternative schedule can also be used at 0, 7d, 21–30d, and a booster at 12m. | Contraindication  
Previous anaphylactic reaction to this vaccine or to any of its components.  
Precautions  
• Moderate or severe acute illness.  
• Pregnancy |
| **Hepatitis B**  
(HepB)  
**Give IM**  
Brands may be used interchangeably. | For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at www.immunize.org/catg.d/p2010.pdf.  
• All adults who want to be protected from hepatitis B virus infection and lack a specific risk factor.  
• Household contacts and sex partners of HBsAg-positive people; injecting drug users; sexually active people not in a long-term, mutually monogamous relationship; men who have sex with men; people with HIV; people seeking STD evaluation or treatment; hemodialysis patients and those with renal disease that may result in dialysis; diabetics younger than age 60yrs (diabetics age 60yrs and older may be vaccinated at the clinician’s discretion [see ACIP recommendations*]); healthcare personnel and public safety workers who are exposed to blood; clients and staff of institutions for the developmentally disabled; inmates of long-term correctional facilities; certain international travelers; and people with chronic liver disease.  
**Note:** Provide serologic screening for immigrants from endemic areas. If patient is chronically infected, assure appropriate disease management. For sex partners and household contacts of HBsAg-positive people, provide serologic screening and administer initial dose of HepB vaccine at same visit. | Give 3 doses on a 0, 1, 6m schedule.  
• Alternative timing options for vaccination include 0, 2, 4m; 0, 1, 4m; and 0, 1, 2, 12m (Engerix brand only).  
• There must be at least 4wks between doses #1 and #2, and at least 8wks between doses #2 and #3. Overall, there must be at least 16wks between doses #1 and #3.  
• Schedule for those who have fallen behind: If the series is delayed between doses, DO NOT start the series over. Continue from where you left off. | For those who have fallen behind:  
• Give 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high.  
Note: Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Previously vaccinated adults can receive 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high. | Contraindication  
Previous anaphylactic reaction to this vaccine or to any of its components.  
Precaution  
Moderate or severe acute illness.  
Pregnancy |
| **Polio**  
(IPV)  
**Give IM or SC** | For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at www.immunize.org/catg.d/p2010.pdf.  
• Not routinely recommended for U.S. residents age 18yrs and older.  
Note: Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Previously vaccinated adults can receive 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high. | • Refer to ACIP recommendations* regarding unique situations, schedules, and dosing information.  
For those who have fallen behind:  
• Give 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high.  
Note: Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Previously vaccinated adults can receive 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high. | Contraindication  
Previous anaphylactic reaction to this vaccine or to any of its components.  
Precautions  
• Moderate or severe acute illness.  
• Pregnancy |
### Vaccine name and route

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccine administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
• All previously unvaccinated women through age 26yrs and men through age 21yrs.  
• All previously unvaccinated men through age 26yrs who 1) have sex with men or 2) are immunocompromised as a result of infection (including HIV), disease, or medications. | • Give 3 doses on a 0, 2, 6m schedule.  
• There must be at least 4wks between doses #1 and #2 and at least 12wks between doses #2 and #3. Overall, there must be at least 24wks between doses #1 and #3. If possible, use the same vaccine product for all three doses. | **Contraindication**  
Previous anaphylactic reaction to this vaccine or to any of its components.  
**Precautions**  
• Moderate or severe acute illness.  
• Pregnancy. |
| **Meningococcal conjugate vaccine, quadrivalent (MCV4) Menactra, Menevo Give IM**  
• People with anatomic or functional asplenia or persistent complement component deficiency.  
• People who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of Sub-Saharan Africa).  
• Microbiologists routinely exposed to isolates of *N. meningitidis*.  
• First year college students through age 21yrs who live in residence halls; see 5th bullet in the box to the right for details. | • Give 2 initial doses of MCV4 separated by 2m to adults 55yrs and younger with risk factors listed in 1st bullet in column to left or if vaccinating adults with HIV infection in this age group. Give 1 dose of MPSV4 to adults 56yrs and older with risk factors.  
• Give 1 initial dose to all other adults with risk factors (see 2nd–4th bullets in column to left).  
• Give booster doses every 5yrs to adults with continuing risk (see the 1st–3rd bullets in column to left for listings of people with possible continuing risk).  
• MCV4 is preferred over MPSV4 for people age 55yrs and younger; use MPSV4 ONLY if age 56yrs or older or if there is a permanent contraindication/precaution to MCV4.  
• For first year college students age 19–21yrs living in residence halls, give 1 initial dose if unvaccinated and give booster dose if most recent dose was given when younger than 16yrs. | **Contraindication**  
Previous anaphylactic reaction to this vaccine or to any of its components.  
**Precaution**  
• Moderate or severe acute illness. |
| **Td, Tdap (Tetanus, diphtheria, pertussis) Give IM**  
• All people who lack written documentation of a primary series consisting of at least 3 doses of tetanus- and diphtheria-toxoid-containing vaccine.  
• A booster dose of Td or Tdap may be needed for wound management, so consult ACIP recommendations.*  
• In pregnancy, when indicated, give Td or Tdap in late 2nd or 3rd trimester. Tdap is preferred because protective antibodies to pertussis are provided to the fetus. If not administered during pregnancy, give Tdap in immediate postpartum period.  
**For Tdap only:**  
• Adults younger than age 65yrs who have not already received Tdap.  
• Adults of any age, including adults age 65yrs and older, in contact with infants younger than age 12m (e.g., parents, grandparents, childcare providers) who have not received a dose of Tdap should be prioritized for vaccination.  
• Healthcare personnel of all ages.  
• Adults age 65yrs and older without a risk indicator (e.g., not in contact with an infant) may also be vaccinated with Tdap. | • For people who are unvaccinated or behind, complete the primary Td series (spaced at 0, 1–2m, 6–12m intervals); substitute a one-time dose of Tdap for one of the doses in the series, preferably the first.  
• Give Tdap booster every 10yrs after the primary series has been completed.  
• Tdap should be given regardless of interval since previous Td. | **Contraindications**  
• Previous anaphylactic reaction to this vaccine or to any of its components.  
• For Tdap only, history of encephalopathy not attributable to an identifiable cause, within 7d following DTP/DTaP.  
**Precautions**  
• Moderate or severe acute illness.  
• Guillian-Barré syndrome within 6wks following previous dose of tetanus-toxoid-containing vaccine.  
• For Tdap only, progressive or unstable neurologic disorder, uncontrolled seizures, or progressive neuropathy until a treatment regimen has been established and the condition has stabilized.  
• History of arthus reaction following a prior dose of tetanus- or diphtheria toxoid-containing vaccine; defer vaccination until at least 10yrs have elapsed since the last tetanus toxoid-containing vaccine. |
age 26. The series should be completed regardless of the age of the patient (i.e., even if the patient is older than 26). In certain situations, some clinicians choose to start the 3-dose HPV series in patients who are older than 26 years. This, however, is an off-label use.

**Will patients who have already had genital warts benefit from receiving Gardasil?**

A history of genital warts or clinically evident genital warts indicates infection with HPV, most often type 6 or 11. However, people with this history might not have been infected with both HPV 6 and 11 or with HPV 16 or 18. Vaccination will provide protection against infection with HPV vaccine types the patient has not already acquired. Gardasil (HPV4) protects against HPV vaccine types 6, 11, 16, and 18; Cervarix (HPV2; GlaxoSmithKline) protects against HPV 16 and 18. Providers should advise their patients/clients that results from clinical trials do not indicate the vaccine will have any therapeutic effect on existing HPV infection or genital warts.

**If a patient has been sexually active for a number of years, is it still recommended to give HPV vaccine or to complete the HPV vaccine series?**

Yes. You should not withhold HPV vaccine from people who are already sexually active. Ideally, patients should be vaccinated before onset of sexual activity; however, patients who have already been infected with one or more HPV types still get protection from other HPV types in the vaccine that have not been acquired.

**If a patient’s vaccination history indicates she received the third dose of HPV vaccine earlier than the recommended minimum interval of 24 weeks, should she be given a fourth dose?**

Maybe. If the 3-dose series was given with minimum intervals of at least 4 weeks between dose #1 and dose #2 AND at least 12 weeks between dose #2 and dose #3, do not repeat any doses. If the third dose was given at less than 12 weeks from dose #2, repeat dose #3 at least 12 weeks after the invalid dose.

**Will VFC cover HPV vaccination for males?**

Yes. VFC funding will cover HPV4 (Gardasil) vaccination for VFC-eligible males age 9 through 18 years.

**If HPV vaccine is given subcutaneously (SC) instead of intramuscularly (IM), does the dose need to be repeated?**

No, the dose does not need to be repeated. Vaccines should always be administered by the route recommended by the manufacturer; however, if a vaccine is inadvertently administered SC instead of IM, or IM instead of SC, ACIP recommends that the dose be counted as valid with two exceptions: Hepatitis B or rabies vaccine administered by a route other than IM should be repeated.

**Tdap vaccine**

Is it true that ACIP no longer specifies a time interval between administering doses of Td and Tdap to teens and adults? In January 2011, CDC issued updated ACIP recommendations (www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a4.htm) on the use of Tdap vaccine. They clearly state that pertussis vaccination, when indicated, should not be delayed and that Tdap should be administered regardless of the interval since the last tetanus- or diphtheria-toxoid-containing vaccine was given. This means that if Td was administered inadvertently when Tdap was indicated, the dose of Tdap can be given on the same day the dose of Td was given.

**If a patient received Tdap vaccine 2 years ago, should I wait approximately 8 more years before administering a dose of Tdap to the patient?**

No. ACIP recommends that people age 11 through 64 who have not yet received Tdap receive their one-time Tdap dose now. ACIP specifies no waiting interval between administering Td and Tdap to anyone in this age group. Adults age 65 years and older do not need to delay Tdap vaccination following Td either.

**If a patient mistakenly received a dose of Td when they should have received Tdap, what is the optimal time to give the missing Tdap dose?**

As soon as possible, even if it is the same day.
Is there any reason not to administer Tdap vaccine to adults age 65 and older who want the vaccine but are not in contact with an infant? It seems like it would be a good idea to vaccinate them to protect them, their family, and their community from pertussis. No medical reason exists for withholding Tdap from adults age 65 and older unless they have a medical contraindication.

We intend to start vaccinating family contacts of pregnant women with Tdap to protect the newborn. Can you tell me how long it takes for the Tdap vaccine to provide protection? To best protect infants, CDC recommends that teens and adults who haven’t been vaccinated receive Tdap 2 weeks or more before having contact with an infant.

### Shingles vaccine

When people are in their 80s, is it still recommended for them to get the shingles vaccine? I’ve heard it doesn’t work as well in the elderly. ACIP recommends the vaccine for everyone age 60 and older, even though the vaccine’s efficacy decreases with the recipient’s age. The clinical trials found approximately an 18% efficacy rate in people age 80 and older as compared with 64% efficacy in people age 60 through 69 years (see pages 13–14 at www.cdc.gov/mmwr/PDF/rr/rr5705.pdf). In general, with increasing age at vaccination, the vaccine was more effective in reducing the severity of zoster and post-herpetic neuralgia than in reducing the occurrence of zoster itself.

### Hib vaccine

Occasionally we have asplenic adult patients who want to get the Hib vaccine. We know it’s given only to infants and young children, but what about using it in this situation? Although the vaccine is not routinely recommended for adults, CDC states in the General Recommendations on Immunization: “No efficacy data are available on which to base a recommendation for use of Hib vaccine for older children and adults with the chronic conditions that are associated with an increased risk for Hib disease. Administering 1 dose of Hib vaccine to these patients who have not previously received Hib vaccine is not contraindicated.” For additional information, consult page 22 of the General Recommendations, published January 2011, at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.

### General vaccine questions

ACIP and CDC’s Vaccine Storage and Handling Guide say that refrigerated vaccines should be stored between 35°–46°F, but some vaccine package inserts list 36°–46°F as the proper range. Should I use 35°F or 36°F as the low boundary of the range? On the Celsius scale, the appropriate storage range for refrigerated vaccines is 2°C–8°C. Because 2°C converts to 35.6°F, some manufacturers have rounded the Fahrenheit reading to 36°F. However, 35°F is still considered acceptable for storage of any refrigerated vaccine. Providers should make an effort to store vaccines toward the midpoint of the range (approximately 40°F or 5°C) rather than at either end of the scale.

What should I do if my thermometer indicates my refrigerated vaccine has been stored between 32°–34°F? Since the vaccine wasn’t “frozen,” will it be OK to use? And what about people who received the vaccine before we discovered the temperature excursion—will we need to revaccinate them? This is a complex question that requires case-by-case review. First, while you’re assessing the situation, return the vaccine to proper storage temperatures and mark it “Do Not Use.” Then, contact your state or local immunization program or the appropriate vaccine manufacturer(s) to discuss the potential usability of the vaccine. They will need to consider several variables related to vaccine storage conditions. For example, their guidance will be affected by the accuracy of the thermometer, whether the thermometer probe was in a liquid or was reading the temperature of the air, the type of vaccine involved, the length of time of the excursion, etc.

In general, if it can be reliably determined that the vaccine in question was not stored below 32°F and the manufacturer’s stability data concurs, most immunization programs and vaccine manufacturers would not recommend wasting the vaccine or revaccinating recipients.

Does the federal law that requires providing patients with VISs apply when administering influenza vaccine to employees and volunteers in hospitals or other workplaces? Yes. Employees and volunteers are considered patients, and you need to provide them with a VIS.

If a vaccine is covered under the National Childhood Vaccine Injury Act—and almost all vaccines routinely administered to adults are (with the exception of PPSV and zoster)—it is mandatory under federal law to give the VIS for that vaccine to the vaccinatee. Therefore, when you give influenza vaccine to employees and staff, you are required by law to provide them with a VIS.

You can find more details about the requirements for using VISs at www.cdc.gov/vaccines/pubs/vis/downloads/vis-Instructions.pdf.

For VISs in multiple languages, go to www.immunize.org/vis.

If you place a needle on a pre-filled syringe and then don’t administer the vaccine, how long can you store the pre-filled syringe with the needle attached? In general, a vaccine should not be prepared until the provider is ready to administer it to a patient. This is because once the syringe cap is removed or a needle is attached, the sterile seal is broken. However, if a sterile seal has been broken, staff should be sure to maintain the syringe at the appropriate temperature and either use it or discard it at the end of the clinic day.

CDC’s Pink Book has a new chapter about vaccine storage and handling at www.cdc.gov/vaccines/pubs/pinkbook/downloads/vac-storage.pdf.
### Order Essential Immunization Resources from IAC

**DVD: Immunization Techniques: Best Practices with Infants, Children, and Adults**

New in 2010 from the California Department of Public Health’s Immunization Branch, this 25-minute DVD helps ensure that staff administer vaccines correctly to all age groups. An excellent training tool, the DVD provides detailed information on these major topics:

- Preparing vaccines—Mixing, reconstituting, and drawing up a variety of vaccine products and preparations
- Administering vaccines—Identifying correct needle lengths, insertion angles, and injection sites, and giving injectable, oral, and nasal-spray vaccines.
- Communicating with parents and patients—Providing VISs, answering questions, and observing patients after vaccination

To order the DVD or any of our other essential immunization resources, print out and mail or fax the form below, or place your order online at [www.immunize.org/shop](http://www.immunize.org/shop).

#### Order Essential Immunization Resources

<table>
<thead>
<tr>
<th>Qty.</th>
<th>Amt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-9 copies—$17 each; 10-24 copies—$10.25 each; 25-49 copies—$7 each</td>
<td>$_______</td>
</tr>
<tr>
<td>D2021 Immunization Techniques: Best Practices with Children/Teens/Adults</td>
<td>$_______</td>
</tr>
<tr>
<td>250 cards/box; 1 box—$45; 2 boxes—$40 each; 3 boxes—$37.50 each; 4 boxes—$34.50 each</td>
<td>$_______</td>
</tr>
<tr>
<td>R2003 Child/teen immunization record cards</td>
<td>$_______</td>
</tr>
<tr>
<td>R2005 Adult immunization record cards</td>
<td>$_______</td>
</tr>
<tr>
<td>R2004 Lifetime immunization record cards</td>
<td>$_______</td>
</tr>
</tbody>
</table>

**Total for Purchases** $_______

#### How to Place an Order

**By Credit Card:** Order easily online at our secure shopping cart at [www.immunize.org/shop](http://www.immunize.org/shop).

**By Check, Purchase Order, or Credit Card:** Print out this page, fill out the necessary information, and

- **Fax the page to:** (651) 647-9131 or
- **Mail the page to:** Immunization Action Coalition 1573 Selby Avenue, Suite 234 St. Paul, MN 55104

Our federal ID# is 41-1768237.

For Questions or International Orders: Contact us by phone at (651) 647-9009 or email [admininfo@immunize.org](mailto:admininfo@immunize.org)

Thank you for your support of the Immunization Action Coalition. We depend on you!

#### Method of payment:

- [ ] Check enclosed (payable to Immunization Action Coalition)
- [ ] Purchase order #

<table>
<thead>
<tr>
<th>Card #</th>
<th>Visa</th>
<th>Mastercard</th>
<th>Am. Express</th>
<th>Discover</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expiration Date</td>
<td>mo/yr</td>
<td>CV Code #*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The CV Code is the Credit Verification Code, the additional 3- or 4-digit number on your credit card.

I am a [ ] new [ ] renewing contributor.

**Here is my contribution:**

- $25 [ ]
- $50 [ ]
- $75 [ ]
- $100 [ ]
- $125 [ ]
- $150 [ ]
- $200 [ ]
- $250 [ ]
- other: $_______

IAC is a 501(c)(3) charitable organization and your contribution is tax deductible to the fullest extent of the law.

**Total for Purchases and Contribution** $_______

---

**It’s convenient to shop IAC online at [www.immunize.org/shop](http://www.immunize.org/shop)**